非缺血性心肌病患者ICD死亡获益取决于左室瘢痕
研究纳入452例符合ICD一级预防指征的非缺血性心肌病心衰患者,基于CMR评估左室瘢痕,中位随访37.9个月。无瘢痕者ICD植入与死亡率改善无关(HR=1.22),有瘢痕者ICD植入独立降低死亡率(HR=0.45)。提示左室瘢痕可优化ICD患者选择。
要点
- 非缺血性心肌病患者中,左室瘢痕者ICD植入与死亡率降低独立相关(HR=0.45)。
- 无左室瘢痕者ICD植入未显示死亡率获益(HR=1.22,95%CI 0.53-2.78)。
- CMR识别的左室瘢痕有助于筛选ICD一级预防的获益人群。
核心结论
- 在非缺血性心肌病患者中,一级预防ICD植入仅在有左室瘢痕的患者中与死亡率降低相关。
研究设计与样本
- 前瞻性队列研究,纳入452例连续的非缺血性心肌病心衰患者(NYHA II/III级,LVEF≤35%),来自全州CMR服务。
- 所有患者符合欧洲心脏病学会ICD一级预防植入指南,但植入决策由治疗医生决定。
- 基线临床和CMR数据前瞻性记录,计算心衰死亡风险(MAGGIC评分),主要终点为全因死亡率。
主要发现
- 中位随访37.9个月,ICD组与非ICD组的MAGGIC评分无差异(19.30±5.46 vs. 18.90±5.67,P=0.50)。
- 无左室瘢痕患者中,ICD植入与死亡率改善无关(HR=1.22,95%CI:0.53-2.78,P=0.64)。
- 有左室瘢痕患者中,ICD植入与死亡率降低独立相关(HR=0.45,95%CI:0.26-0.77,P=0.003)。
临床怎么用
- 对于非缺血性心肌病且LVEF≤35%的患者,可考虑通过CMR评估左室瘢痕以筛选ICD一级预防的获益人群。
- 无左室瘢痕的患者可能无法从ICD植入中获得死亡率获益,需个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In patients with non-ischaemic cardiomyopathy (NICM), the mortality benefit of a primary prevention implantable cardioverter-defibrillator (ICD) has been challenged. Left ventricular (LV) scar identified by cardiac magnetic resonance (CMR) imaging is associated with a high risk of malignant arrhythmia in NICM. We aimed to determine the impact of LV scar on the mortality benefit from a primary prevention ICD in NICM. METHODS AND RESULTS: We recruited 452 consecutive heart failure patients [New York Heart Association (NYHA) Class II/III] with NICM and LV ejection fraction ≤35% from a state-wide CMR service. All patients fulfilled European Society of Cardiology guidelines for primary prevention ICD implantation; however, the decision to implant was at the treating physician's discretion. Baseline clinical and CMR data were recorded prospectively and heart failure mortality risk (MAGGIC score) was calculated. The primary study outcome measurement was all-cause mortality based on presence or absence of ICD, stratified by LV scar. Median follow-up was 37.9 months and there was no difference in MAGGIC score between those who did and did not receive a primary prevention ICD (19.30 ± 5.46 vs. 18.90 ± 5.67, P = 0.50). In patients without LV scar, ICD implantation was not associated with improved mortality [hazard ratio (HR) = 1.22, 95% confidence interval (CI): 0.53-2.78, P = 0.64]. In patients with LV scar, ICD implantation was independently associated with reduced mortality (HR = 0.45, 95% CI: 0.26-0.77, P = 0.003). CONCLUSIONS: In patients with NICM, primary prevention ICD implantation is only associated with reduced mortality in patients with LV scar. This may enable more effective selection of NICM patients for ICD implantation compared with current guidelines.
引用
- Gutman SJ, Costello BT, Papapostolou S, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J. 2019. PMID: 30107489. doi:10.1093/eurheartj/ehy437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。